Mixing & Matching Covaxin, Covishield Shows Better Result: ICMR

New Delhi located Indian Council of Medical Research (ICMR) has claimed that a study on mixing and matching  Covaxin and Covishield vaccines against Covid -19 demonstrated better results as the cumulative number of COVID-19 vaccine doses administered to Indians has crossed 50.10 crores. India’s total population is estimated at 135 crores. Immunisation with a combination of an adenovirus vector platform-based vaccine followed by inactivated whole virus vaccine was not only safe but also elicited better immunogenicity, the study said. An expert panel of Drugs Controller General of India (DCGI) had last month recommended conducting a study on mixing Covaxin and Covishield vaccines’ doses say ANI on Tweeter. Madhya Pradesh, Gujarat, Rajasthan, Maharashtra and Uttar Pradesh have administered more than one crore cumulative doses of COVID-19 Vaccine in the age group of  18 to 44 years. Andhra Pradesh, Assam, Chhattisgarh, Delhi, Haryana, Jharkhand, Kerala, Telangana, Himachal Pradesh, Odisha, Punjab, Uttarakhand and West Bengal have vaccinated more than 10 lakh beneficiaries of the age group of 18 to 44 years for the first dose of COVID vaccine.  Meanwhile, Johnson & Johnson’s single Covid-19 has been given Emergency Use Approval in India for further boosting the country’s collective fight against coronavirus infection, said Health  Minister Mansukh Mandaviya. The US-based pharma company had applied for Emergency Use Authorization on Friday, August 6. Besides J & J, the other four  covid-19 vaccines that allowed EUA are COVAXIN, COVISHIELD, SPUTNIK V and MODERNA. Incidentally, Moderna is also manufactured by an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. Edited by @chakravartypk